
Neogenomics Launches Comprehensive Genomic Profiling Test for Hematomalignancies; Could Be a Strong Compliment to Existing Anatomic Pathology Franchise
NeoGenomics, Inc. has unveiled two new tests, expanding their portfolio of cancer diagnostic products. The new tests are Neo Comprehensive™ – Heme Cancers, a next-generation sequencing (NGS) panel delivering a comprehensive genomic profile of hematologic malignancies, and the Early-stage Non-Small Cell Lung Cancer (NSCLC) Panel, a therapy selection panel tailored for early-stage NSCLC patients. NeoGenomics is a leader in anatomical pathology services for hematomalignancies and consequently, the Neo Comprehensive™ – Heme Cancers NGS test could be a strong compliment given it receives a significant number of samples every year for these cancers already. Previously the company had offered specific gene panels for these diseases and in March 2023 the company launched an NGS test specifically focused on myeloid disorders.
Neo Comprehensive™ – Heme Cancers is a comprehensive genomic profile (CGP) that scrutinizes 433 genes associated with various forms of hematologic malignancies from myeloid and lymphoid lineages. It detects single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variants (CNVs), and fusions using DNA and RNA NGS techniques. Aligned with the latest guidelines and the WHO 5th Edition Classification of Haematolymphoid Tumours, this panel offers diagnostic information, aiding therapeutic approaches, risk stratification, prognosis prediction, and clinical research.
The Early-stage NSCLC Panel is NeoGenomics’ most focused early-stage lung cancer panel, identifying genomic alterations and gene expression in key biomarkers relevant to diagnosis, therapy selection, prognosis, and clinical trials. The panel includes genetic markers such as EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS (reactive oxygen species), and PD-L1 (programmed death-ligand 1). These markers are presented in a streamlined test report format. This panel enhances existing single-gene tests by simplifying the ordering process and standardizing evidence-based multi-biomarker testing. By combining information on genetic alterations and PD-L1 expression, it provides a comprehensive foundation for targeted therapy decisions.
Warren Stone, President of Clinical Services at NeoGenomics, emphasized the significance of these new panels for oncologists, offering crucial data to personalize cancer care and enhance patient outcomes. Biomarker-informed therapy selection plays a pivotal role in improving patient results. Stone stated, “The commercial availability of these new panels highlights our mission to save lives by improving patient care, using biomarker testing paired with our uncompromising quality and exceptional service.”